US approves Ranbaxy's generic Biaxin antibiotic
By siliconindia staff writer
|
Monday, 27 September 2004, 19:30 IST
MUMBAI: Ranbaxy Laboratories Ltd has received the US Food and Drug Administration's approval for clarithromycin, a generic form of Abbott Laboratories Inc's antibiotic Biaxin, the FDA said on Saturday.
Biaxin had sales worth $538 million in the US in 2003.
Earlier this year, the FDA had approved generic Biaxin forms from Andrx Corp and Roxane Laboratories.